new oral glp 1 agonist GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Oral - Glp-1 receptor agonist

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Drug Trials Snapshots: DEFENCATH HOW TO USE THIS SNAPSHOT The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups

The researchers got half of their subjects to apply a solution that consisted of 2 percent L-carnitine-L-tartrate to the skin on their head twice a day

doi: 10.1021/jf204763f, 124

M.PapagiannakopoulosT.MoreiraA